MINERALYS THERAPEUTICS INC. - COMMON STOCK

Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

12 أغسطس 2025 13:05:01 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

04 أغسطس 2025 13:05:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

30 يونيو 2025 08:17:45 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

17 يونيو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)

24 مايو 2025 01:30:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

20 مايو 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

12 مايو 2025 13:05:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

07 مايو 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025

05 مايو 2025 13:05:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)

23 أبريل 2025 14:23:03 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

29 مارس 2025 11:30:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

25 مارس 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

18 مارس 2025 13:01:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo

17 مارس 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

11 مارس 2025 19:20:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

10 مارس 2025 13:01:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

10 مارس 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

07 مارس 2025 13:01:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

12 فبراير 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025

05 فبراير 2025 13:05:00 بحسب Nasdaq GlobeNewswire